CD274 and metastatic melanoma: Brahmer's group reported that expression of PD-L1 was neither prognostic nor predictive of benefit in squamous-cell NSCLC [6]; however, Larkin's group suggested that metastatic melanoma patients with positive PD-L1 expression may benefit from anti-PD-1 therapy [19].